Identification of microRNA which regulates peritoneal dissemination of ovarian cancer

卵巢癌是一种以广泛的腹膜扩散和腹水为特征的高度转移性肿瘤，是妇科恶性肿瘤死亡的主要原因。我们先前已经确定整合素α5通过抑制腹膜扩散而成为卵巢癌治疗的新靶点。我们的目的是寻找新的调控整合素α5表达的微RNA，并分析靶向其微RNA的治疗潜力。基于microRNA算法搜索，我们确定hsa-mir-92a为候选。HSA-Mir-92a在高表达整合素α5的卵巢癌细胞中低水平表达，而在不表达整合素α5的RMUG-S细胞中高表达。前体Mir-92a转染卵巢癌细胞后，整合素α5表达降低，并伴随着细胞黏附和侵袭的抑制。这些结果表明，通过抑制整合素α5的表达，靶向hsa-mir-92a可能是一种有希望的卵巢癌患者亚群的治疗方法。

Ovarian cancer is a highly metastatic characterized by widespread peritoneal dissemination and ascites, and is the leading cause of death from gynecological malignancy. We have previously identified integrinα5 as a new target in ovarian cancer treatment by inhibiting peritoneal dissemination. Our aim is to identify new microRNA which regulates the expression of integrinα5 and analyze the therapeutic potential of targeting of its microRNA. Based on the microRNA algorism search, we identified hsa-mir-92a as a candidate. Hsa-mir-92a is little expressed in ovarian cancer cells which express high level of integrinα5, whereas hsa-mir-92a is highly expressed in RMUG-S cells which do not express integrinα5. Transfection of precursor mir-92a reduced integrinα5 expression in ovarian cancer cells, accompanied by the inhibition of cell adhesion and invasion. Those results suggested targeting hsa-mir-92a could be a promising therapy for a subset of ovarian cancer patients by inhibiting integrin α5 expression.